UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
10-Q
| x | Quarterly
Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. |
For the quarterly
period ended September 30, 2014
| ¨ | Transition
Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. |
For the transition
period from________ to ________
Commission File
Number: 0-19266
ALLIED
HEALTHCARE PRODUCTS, INC.
(Exact name
of registrant as specified in its charter)
Delaware |
|
25-1370721 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
Incorporation or organization) |
|
Identification No.) |
1720
Sublette Avenue, St. Louis, Missouri 63110
(Address of
principal executive offices, including zip code)
(314) 771-2400
(Registrant’s
telephone number, including area code)
N/A
(Former name,
former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
twelve months (or for such shorter periods that the registrant was required to file such reports, and (2) has been subject to
such filing requirements for the past ninety days. Yes x No ¨
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of
"large accelerated filer,” “accelerated filer" and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer |
¨ |
Accelerated filer |
¨ |
|
|
|
|
Non-accelerated filer |
¨ (Do not check if smaller reporting company) |
Smaller reporting company |
x |
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).
Yes ¨
No x
The number of shares of common stock outstanding at November
4, 2014 is 8,027,147 shares.
"SAFE HARBOR" STATEMENT UNDER
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements contained
in this Report, which are not historical facts or information, are "forward-looking statements." Words such as "believe,"
"expect," "intend," "will," "should," and other expressions that indicate future events
and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, which could
cause the outcome and future results of operations, and financial condition to be materially different than stated or anticipated
based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks
and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, both in the United
States and in our overseas markets, impacts of the U.S. Affordable Care Act, the outcome of litigation proceedings and specific
matters which relate directly to the Company's operations and properties as discussed in the Company’s annual report on
Form 10-K for the year ended June 30, 2014. The Company cautions that any forward-looking statements contained in this report
reflect only the belief of the Company or its management at the time the statement was made. Although the Company believes such
forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete.
The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date
on which the statement was made.
PART
I. FINANCIAL INFORMATION
| Item
1. | Financial
Statements |
ALLIED
HEALTHCARE PRODUCTS, INC.
STATEMENT
OF OPERATIONS
(UNAUDITED)
| |
Three months ended | |
| |
September 30, | |
| |
2014 | | |
2013 | |
| |
| | |
| |
Net sales | |
$ | 8,845,267 | | |
$ | 8,708,297 | |
Cost of sales | |
| 7,270,484 | | |
| 6,947,731 | |
Gross profit | |
| 1,574,783 | | |
| 1,760,566 | |
| |
| | | |
| | |
Selling, general and | |
| | | |
| | |
administrative expenses | |
| 2,272,288 | | |
| 2,622,202 | |
Loss from operations | |
| (697,505 | ) | |
| (861,636 | ) |
| |
| | | |
| | |
Other (income) expenses: | |
| | | |
| | |
Interest income | |
| (755 | ) | |
| (1,890 | ) |
Other, net | |
| 11,425 | | |
| 8,723 | |
| |
| 10,670 | | |
| 6,833 | |
| |
| | | |
| | |
Loss before benefit from income taxes | |
| (708,175 | ) | |
| (868,469 | ) |
Benefit from income taxes | |
| - | | |
| (277,910 | ) |
Net loss | |
($ | 708,175 | ) | |
($ | 590,559 | ) |
| |
| | | |
| | |
Basic and diluted loss per share | |
($ | 0.09 | ) | |
($ | 0.07 | ) |
| |
| | | |
| | |
Weighted average shares outstanding - basic and diluted | |
| 8,027,147 | | |
| 8,027,147 | |
See
accompanying Notes to Financial Statements.
ALLIED
HEALTHCARE PRODUCTS, INC.
BALANCE SHEET
ASSETS
| |
(Unaudited) | | |
| |
| |
September 30, | | |
June 30, | |
| |
2014 | | |
2014 | |
| |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 1,724,227 | | |
$ | 1,366,762 | |
Accounts receivable, net of allowances of $170,000 | |
| 3,567,469 | | |
| 3,713,105 | |
Inventories, net | |
| 9,567,714 | | |
| 9,406,098 | |
Income tax receivable | |
| 27,791 | | |
| 17,166 | |
Other current assets | |
| 479,764 | | |
| 410,098 | |
Total current assets | |
| 15,366,965 | | |
| 14,913,229 | |
| |
| | | |
| | |
Property, plant and equipment, net | |
| 8,663,959 | | |
| 8,935,601 | |
Deferred income taxes | |
| 1,996,434 | | |
| 1,996,434 | |
Other assets, net | |
| 173,275 | | |
| 187,163 | |
Total assets | |
$ | 26,200,633 | | |
$ | 26,032,427 | |
See accompanying
Notes to Financial Statements.
(CONTINUED)
ALLIED HEALTHCARE
PRODUCTS, INC.
BALANCE SHEET
(CONTINUED)
LIABILITIES
AND STOCKHOLDERS' EQUITY
| |
(Unaudited) | | |
| |
| |
September 30, | | |
June 30, | |
| |
2014 | | |
2014 | |
| |
| | |
| |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,537,753 | | |
$ | 1,068,222 | |
Other accrued liabilities | |
| 2,029,443 | | |
| 1,624,186 | |
Deferred income taxes | |
| 830,946 | | |
| 830,946 | |
Total current liabilities | |
| 4,398,142 | | |
| 3,523,354 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders' equity: | |
| | | |
| | |
Preferred stock; $0.01 par value; 1,500,000 shares
authorized; no shares issued and outstanding | |
| - | | |
| - | |
Series A preferred stock; $0.01 par value; 200,000
shares authorized; no shares issued and outstanding | |
| - | | |
| - | |
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878
shares issued at September 30, 2014 and June 30, 2014; 8,027,147 shares outstanding at September 30, 2014 and June
30, 2014 | |
| 104,279 | | |
| 104,279 | |
Additional paid-in capital | |
| 48,586,829 | | |
| 48,585,236 | |
Accumulated deficit | |
| (5,907,829 | ) | |
| (5,199,654 | ) |
Less treasury stock, at cost;
2,400,731 shares at September 30, 2014 and June 30, 2014 | |
| (20,980,788 | ) | |
| (20,980,788 | ) |
Total stockholders' equity | |
| 21,802,491 | | |
| 22,509,073 | |
Total liabilities and stockholders'
equity | |
$ | 26,200,633 | | |
$ | 26,032,427 | |
See accompanying
Notes to Financial Statements.
ALLIED
HEALTHCARE PRODUCTS, INC.
STATEMENT
OF CASH FLOWS
(UNAUDITED)
| |
Three months ended | |
| |
September 30, | |
| |
2014 | | |
2013 | |
| |
| | |
| |
Cash flows from operating activities: | |
| | | |
| | |
Net loss | |
($ | 708,175 | ) | |
($ | 590,559 | ) |
Adjustments to reconcile net loss to net | |
| | | |
| | |
cash provided by (used in) operating activities:
| |
| | | |
| | |
| |
| | | |
| | |
Depreciation and amortization | |
| 334,693 | | |
| 304,975 | |
Stock based compensation | |
| 1,593 | | |
| 4,955 | |
Provision for doubtful accounts and sales | |
| | | |
| | |
returns and allowances | |
| 13,248 | | |
| (1,399 | ) |
Deferred taxes | |
| - | | |
| (277,910 | ) |
| |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| 132,388 | | |
| 597,587 | |
Inventories | |
| (161,616 | ) | |
| (907,349 | ) |
Income tax receivable | |
| (10,625 | ) | |
| (11,754 | ) |
Other current assets | |
| (69,666 | ) | |
| (185,968 | ) |
Accounts payable | |
| 469,531 | | |
| 378,462 | |
Other accrued liabilities | |
| 405,257 | | |
| 265,715 | |
Net cash provided by (used in) operating activities | |
| 406,628 | | |
| (423,245 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Capital expenditures | |
| (49,163 | ) | |
| (187,542 | ) |
Net cash used in investing activities | |
| (49,163 | ) | |
| (187,542 | ) |
| |
| | | |
| | |
Net increase (decrease) in cash and cash equivalents | |
| 357,465 | | |
| (610,787 | ) |
Cash and cash equivalents at beginning
of period | |
| 1,366,762 | | |
| 3,687,919 | |
Cash and cash equivalents at end of
period | |
$ | 1,724,227 | | |
$ | 3,077,132 | |
See
accompanying Notes to Financial Statements.
ALLIED
HEALTHCARE PRODUCTS, INC.
NOTES TO
FINANCIAL STATEMENTS
(UNAUDITED)
1. Summary of Significant Accounting
and Reporting Policies
Basis of Presentation
The
accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared
in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting
principles generally accepted in the United States of America for complete financial statements. In the opinion of management,
all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included.
Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These
statements should be read in conjunction with the financial statements and notes to the financial statements thereto included
in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014.
Recently
Issued Accounting Guidance
In May 2014, the FASB
issued ASU No. 2014-09, "Revenue from Contracts with Customers." This ASU is a comprehensive new revenue recognition
model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that
reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting
periods beginning after December 15, 2016 and early adoption is not permitted. Accordingly, we will adopt this ASU on January 1,
2017. Companies may use either a full retrospective or modified retrospective approach to adopt this ASU and we are currently evaluating
which transition approach to use and the full impact this ASU will have on our future financial statements.
The
FASB has issued Accounting Standards Update (ASU) No. 2014-15, “Presentation of Financial Statements—Going Concern
(Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” ASU
2014-15 establishes the responsibility of management to assess an organization’s ability to continue as a going concern and
to provide related footnote disclosures. The ASU is effective for annual periods ending after December 15, 2016, and interim
periods within annual periods beginning after December 15, 2016. We do not expect the adoption of this ASU to have an impact
on our future financial statements.
Fair Value of Financial Instruments
The Company’s
financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying amounts for
cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short maturity of
these instruments.
2. Inventories
Inventories are comprised as follows:
| |
September 30, 2014 | | |
June 30, 2014 | |
| |
| | |
| |
Work-in progress | |
$ | 667,632 | | |
$ | 616,474 | |
Component parts | |
| 7,664,250 | | |
| 7,605,543 | |
Finished goods | |
| 2,664,707 | | |
| 2,617,799 | |
Reserve for obsolete and excess | |
| | | |
| | |
inventories | |
| (1,428,875 | ) | |
| (1,433,718 | ) |
| |
$ | 9,567,714 | | |
$ | 9,406,098 | |
3. Earnings per share
Basic
earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted
earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents
outstanding during the period. The number of basic and diluted shares outstanding for the three months ended September 30, 2014
and 2013 were 8,027,147.
4. Commitments and Contingencies
Legal Claims
The Company is subject to various investigations, claims and legal proceedings covering a wide range of
matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such
a manner as to avoid FDA actions seeking to interrupt or suspend manufacturing or require any recall or modification of products.
The
Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which,
in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information
currently available, management believes that existing accrued liabilities are sufficient and that it is not reasonably possible
at this time that any additional liabilities will result from the resolution of these matters that would have a material adverse
effect on the Company’s results of operations, financial position, or cash flows.
Stuyvesant Falls Power Litigation.
The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”)
and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls, New York. In fiscal year
2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. The Company
maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running
with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices were stopped in
December 2010 by a temporary restraining order. Among other things, Niagara seeks as damages the value of electricity received
by the Company without charge. While the total value of electricity at issue in the litigation is not known with certainty, Niagara
alleges in its Motion for Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity since
May 2010. Alternatively, Niagara asserts that, in the event that the free power covenant is still enforceable, the Company is still
responsible for delivery fees relating to any free power to which it is entitled. The Company filed its own Motion for Summary
Judgment on March 14, 2014, seeking dismissal of Niagara’s claims; and oral arguments on the motions were held on June 13,
2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled that the Company
is entitled to receive electrical power pursuant to the power covenants. As of September 30, 2014, the Company has not recorded
a provision for this matter as management intends to defend against any further litigation and to enforce its rights under the
subject power covenants.
Dräger
Patent Litigation. On or about October 4, 2013, Dräger Medical GmbH and certain affiliates (the “Dräger Plaintiffs”)
filed a patent infringement lawsuit against the Company in the United States District Court for the District of Delaware, asserting
that the Company infringes United States Patent Nos. 7,487,776 and 8,286,633, both protecting particular combinations of carbon
dioxide absorption cartridges and adapters which fit on anesthesia machines. The Dräger Plaintiffs assert that the Company’s
sales of certain models of its Litholyme and Carbolime single-use carbon dioxide absorption cartridges infringe both patents. The
Company answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license under the doctrine of
permissive repair.
On October 25,
2013, the Dräger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling
certain models of its Litholyme and Carbolime cartridges during the pendency of the litigation. A hearing on the motion for preliminary
injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in the Company’s favor and denied Dräger’s
motion for a preliminary injunction, stating among other things that Dräger had not carried its burden of showing that the
Company had infringed Dräger’s patents. On June 20, 2014, the Company filed a motion seeking summary judgment based
on the repair doctrine, which was the basis for the Court’s denial of Dräger’s motion for preliminary injunction.
The Company’s motion and Dräger’s response is currently under submission to the Court.
As
of September 30, 2014, the Company has not recorded a provision for this matter because the Company cannot estimate a possible
loss or range of loss for this matter because the Dräger Plaintiffs have not specified damages claimed and the proceedings
are in the early stages. The Company intends to defend against any further litigation brought by the Dräger Plaintiffs and
pursue counterclaims for invalidity, non-infringement, and implied license.
Employment Contract
The
Company has entered into an employment contract with its chief executive officer with annual renewals. The contract includes termination
without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance
payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily
terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of
his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement
and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined
in the Agreement.
5. Financing
The
Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit
Agreement”) pursuant to which the Company obtained a secured revolving credit facility. Currently, the agreement provides
for borrowing availability of up to $5,000,000 (the “Credit Facility”). At September 30, 2014, the Company had $5,000,000
available for borrowing on the line of credit. The Company’s obligations under the Credit Facility are secured by certain
assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.
The Credit Facility
was amended on November 10, 2014 extending the maturity date to November 9, 2015. The Credit Facility will be available on a revolving
basis until it expires on November 9, 2015, at which time all amounts outstanding under the Credit Facility will be due and payable.
Advances under the Credit Facility will be made pursuant to a Revolving Credit Note (as defined in the Credit Agreement) executed
by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 3.50% in excess of
the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.
Under
the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants
with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s
ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or
issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell
certain of its assets or dissolve or wind up the Company. The Credit Agreement also contains certain events of default that are
customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts
when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other
indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance
or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings;
and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect.
After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility
would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest
rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment
of the Company’s obligations under the Credit Facility.
The
30-day LIBOR rate was 0.15% on September 30, 2014.
At
September 30, 2014 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term
debt.
The
Company was in compliance with all of the covenants associated with the Credit Facility at September 30, 2014.
6.
Income Taxes
The Company accounts
for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using
the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial
statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established
when necessary to reduce deferred tax assets to the amounts expected to be realized. In the quarter ended September 30, 2014
the Company recorded the tax benefit of losses incurred during the current quarter in the amount of approximately $266,000.
As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of approximately
$266,000 was also recorded. The total valuation allowance recorded by the Company as of September 30, 2014 was approximately $1,066,000.
To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses will be subject to a
valuation allowance.
Item 2. Management’s
Discussion and Analysis of Financial Conditions and Results of Operations
Three months ended September
30, 2014 compared to three months ended September 30, 2013
Allied
had net sales of $8.8 million for the three months ended September 30, 2014, up $0.1 million from net sales of $8.7 million in
the prior year same quarter. Domestic sales were down 1.9% while international sales, which represented 25.5% of first quarter
sales, were up 13.4% from the prior year same quarter.
Orders for
the Company’s products for the three months ended September 30, 2014 of $9.3 million were $0.5 million or 5.7% higher than
orders for the prior year same quarter of $8.8 million. Domestic orders are down 1.2% over the prior year same quarter while international
orders, which represented 29.2% of first quarter orders, were 27.6% higher than orders for the prior year same quarter. The Company
continues to believe that the purchase of equipment and durable goods and the purchase of equipment by hospitals and municipalities
have been reduced since the 2008 recession and subsequent slow recovery. The Company also believes domestic markets are further
negatively impacted by uncertainty from the implementation of the Affordable Care Act. Orders and sales remain below pre-recession
levels. International sales and orders are subject to fluctuation in international demand. These fluctuations are at times due
to political uncertainty internationally. International sales continue to be impacted by political uncertainty in regions and
countries such as Russia, Ukraine, and Venezuela.
Gross profit for the
three months ended September 30, 2014 was $1.6 million, or 18.2% of net sales, compared to $1.8 million, or 20.7% of net sales,
for the three months ended September 30, 2013. Gross profit for the quarter was negatively impacted by lower utilization of fixed
expenses in the Company’s manufacturing operations as a result of lower production levels compared to the same quarter a
year ago.
Selling,
general and administrative expenses for the three months ended September 30, 2014 were $2.3 million compared to selling, general
and administrative expenses of $2.6 million for the three months ended September 30, 2013. Personnel cost, primarily salaries
and fringe benefits, decreased by approximately $0.2 million. Legal expenses decreased by approximately $53,000.
Loss
from operations was $697,505 for the three months ended September 30, 2014 compared to loss from operations of $861,636 for the
three months ended September 30, 2013.
Allied had a loss
before benefit from income taxes in the first quarter of fiscal 2015 of $708,175 compared to a loss before benefit from
income taxes in the first quarter of fiscal 2014 of $868,469. The Company’s tax provision net of valuation
allowance reflects a tax benefit of $0 for the three months ended September 30, 2014 compared to a tax benefit of $277,910 for
the three months ended September 30, 2013. In the quarter ended September 30, 2014 the tax benefit of losses in the amount of
approximately $266,000 was fully offset by a valuation allowance of equivalent amount. To the extent that the
Company’s losses continue in future quarters, the tax benefit of those losses will be fully offset by a valuation
allowance.
Net
loss for the first quarter of fiscal 2015 was $708,175 or $0.09 per basic and diluted share compared to net loss of $590,559 or
$0.07 per basic and diluted share for the first quarter of fiscal 2014. The weighted average number of common shares outstanding,
used in the calculation of basic and diluted earnings per share for the first quarters of fiscal 2015 and 2014 were 8,027,147.
Liquidity and Capital Resources
The
Company believes that available resources, including availability under a credit facility described below, are sufficient to meet
operating requirements in the coming year.
The Company’s
working capital was $11 million at September 30, 2014 compared to $11.4 million at June 30, 2014. Cash increased by approximately
$0.4 million and Inventories increased by approximately $0.2 million. During fiscal 2015, these increases in working capital were
offset by a $0.5 million increase in Accounts Payable and a $0.4 million increase in Other Accrued Liabilities. Accounts Payable
and Other Accrued Liabilities are subject to normal fluctuations in purchasing levels and the timing of payments within the quarter.
The change during this quarter does not represent a change in payment policy or cash availability. Accounts Receivable declined
primarily due to the decrease in Sales from the fourth quarter of fiscal year 2014. Accounts Receivable was $3.6 million at September
30, 2014, a decrease from $3.7 million at June 30, 2014. Accounts Receivable as measured in days sales outstanding (“DSO”)
was 39 DSO at September 30, 2014; up from 36 DSO at June 30, 2014. The Company does adjust product forecast, order quantities and
safety stock based on changes in demand patterns in order to manage inventory levels.
The
Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit
Agreement”) pursuant to which the Company has a secured revolving credit facility with borrowing availability of up to $5,000,000
(the “Credit Facility”). At September 30, 2014, the Company had $5,000,000 available for borrowing on the line of
credit. The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the
terms and subject to the conditions set forth in the Credit Agreement. See Note 5 – Financing to the Company’s unaudited
financial statements for more information concerning the Credit Facility.
Any advances under
the Credit Facility will be made pursuant to a Revolving Credit Note (as defined in the Credit Agreement) executed by the Company
in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to the 30-day LIBOR rate plus 3.50%.
Advances may be prepaid in whole or in part without premium or penalty. The 30-day LIBOR rate was 0.15% on September 30, 2014.
Management
has implemented cost saving measures which it believes will reduce the Company’s usage of cash, including overhead reductions
and deferral of non-essential capital expenditures, however there are no assurances that these measures will be successful. If
these cost saving measures are not successful, the Company may need to borrow under the Credit Facility to fund its operations.
The Credit Facility expires on November 9, 2015, at which time any outstanding borrowings would be due and payable, with interest.
If the Company does not have sufficient cash to repay any outstanding principal and interest under the Credit Facility, it would
be required to refinance the Credit Facility. While the Company believes that in such event it would have a sufficient borrowing
base to secure the necessary financing, the Company could incur additional costs due to higher interest rates or fees. At September
30, 2014 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.
Inflation
has not had a material effect on the Company’s business or results of operations during the first quarter of fiscal 2015.
Litigation and Contingencies
The Company becomes,
from time to time, a party to personal injury litigation arising out of incidents involving the use of its products. The Company
believes that any potential judgments resulting from these claims over its self-insured retention will be covered by the Company’s
product liability insurance. See Part II, Item 1 – Legal Proceedings, below, for more information concerning litigation.
Critical Accounting Policies
The
impact and any associated risks related to the Company’s critical accounting policies on business operations are discussed
throughout “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” where such
policies affect the Company’s reported and expected financial results. For a detailed discussion on the application of these
and other accounting policies, see the Company’s Annual Report on Form 10-K for the year ended June 30, 2014.
Recently
Issued Accounting Guidance
See
Note 1 – Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements
and their impact, if any, on the Company’s financial statements. Management believes there have been no material changes
to our critical accounting policies.
| Item
3. | Quantitative
and Qualitative Disclosure about Market Risk |
At
September 30, 2014, the Company did not have any debt outstanding. The revolving credit facility bears an interest rate using
the 30-day LIBOR rate as the basis, as defined in the loan agreement, and therefore is subject to additional expense should there
be an increase in market interest rates while borrowing on the revolving credit facility.
The Company had no
holdings of derivative financial or commodity instruments at September 30, 2014. The Company has international sales; however,
these sales are denominated in U.S. Dollars, mitigating foreign exchange rate fluctuation risk.
| Item
4. | Controls
and Procedures |
Evaluation
of Disclosure Controls and Procedures
The
Company maintains controls and procedures designed to ensure that information required to be disclosed in the reports that the
Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the
time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated
and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate,
to allow timely decisions regarding required disclosure. Based upon their evaluation of those controls and procedures performed
as of September 30, 2014, the Chief Executive Officer and Chief Financial Officer of the Company concluded that its disclosure
controls and procedures were effective.
Changes
in internal control over financial reporting
There
were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2014 that
have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial
reporting.
| Part II. | OTHER
INFORMATION |
Item 1.
Legal Proceedings
Dräger
Medical GmbH, Draeger Medical Systems, Inc. and Draeger Medical Inc. v. Allied Healthcare Products, Inc., filed in the United
States District Court for the District of Delaware, Case No. 1:13-cv-01656-SLR. On or about October 4, 2013, Dräger Medical
GmbH and certain affiliates (the “Dräger Plaintiffs”) filed a patent infringement lawsuit against Allied in the
District of Delaware, asserting that Allied infringes United States Patent Nos. 7,487,776 and 8,286,633, both protecting particular
combinations of carbon dioxide absorption cartridges and adapters which fit on anesthesia machines. The Dräger Plaintiffs
assert that Allied’s sales of certain models of its Litholyme and Carbolime single-use carbon dioxide absorption cartridges
infringe both patents. Allied has answered the Complaint, asserting invalidity of the patents, non-infringement, and implied license
under the doctrine of permissive repair.
On October 25, 2013,
the Dräger Plaintiffs filed a motion for preliminary injunction requesting that the Company be enjoined from selling certain
models of its Litholyme and Carbolime cartridges during the pendency of the litigation. A hearing on the motion for preliminary
injunction was held on February 7, 2014. On March 24, 2014, the Court ruled in Allied’s favor and denied Dräger’s
motion for a preliminary injunction, stating among other things that Dräger had not carried its burden of showing that Allied
had infringed Dräger’s patents. On June 20, 2014, the Company filed a motion seeking summary judgment based on the repair
doctrine, which was the basis for the Court’s denial of Dräger’s motion for preliminary injunction. The Company’s
motion and Dräger’s response is currently under submission to the Court.
As of September
30, 2014, the Company has not recorded a provision for this matter because the Company cannot estimate a possible loss or range
of loss for this matter because the Dräger Plaintiffs have not specified damages claimed and the proceedings are in the early
stages. The Company intends to defend against any further litigation brought by the Dräger Plaintiffs and pursue counterclaims
for invalidity, non-infringement, and implied license.
31.1 Certification of
Chief Executive Officer (filed herewith)
31.2 Certification of
Chief Financial Officer (filed herewith)
32.1 Sarbanes-Oxley Certification
of Chief Executive Officer (furnished herewith)*
32.2 Sarbanes-Oxley Certification
of Chief Financial Officer (furnished herewith)*
101.INS XBRL Instance
Document**
101.SCH XBRL Taxonomy
Extension Schema Document**
101.CAL XBRL Taxonomy
Extension Calculation Linkbase Document**
101.DEF XBRL Taxonomy
Extension Definition Linkbase Document**
101.LAB XBRL Taxonomy
Extension Label Linkbase Document**
101.PRE XBRL Taxonomy
Extension Presentation Linkbase Document**
*Notwithstanding
any incorporation of this Quarterly Report on Form 10-Q in any other filing by the Registrant, Exhibits furnished herewith and
designated with an asterisk (*) shall not be deemed incorporated by reference to any other filing under the Securities Act of
1933 or the Securities Exchange Act of 1934 unless specifically otherwise set forth therein.
**Filed herewith
as Exhibit 101 are the following materials formatted in XBRL: (i) Statement of Operations, (ii) Balance Sheet, (iii) Statement
of Cash Flows and (iv) Notes to Financial Statements.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
ALLIED HEALTHCARE PRODUCTS, INC. |
|
|
|
/s/ Daniel C. Dunn |
|
Daniel C. Dunn |
|
Chief Financial Officer |
|
|
|
Date: November 12, 2014 |
Exhibit 31.1
CERTIFICATION
I, EARL R. REFSLAND, certify that:
1. I have reviewed this Form 10-Q of ALLIED
HEALTHCARE PRODUCTS, INC.;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a. Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b. Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change
in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter
(the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant's ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 12, 2014
|
/s/ EARL R. REFSLAND |
|
Earl. R. Refsland |
|
President & Chief Executive Officer |
Exhibit 31.2
CERTIFICATION
I, DANIEL C. DUNN, certify that:
1. I have reviewed this Form 10-Q of ALLIED
HEALTHCARE PRODUCTS, INC.;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a. Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b. Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change
in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter
(the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely
to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant's ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 12, 2014
|
/s/ DANIEL C. DUNN |
|
Daniel C. Dunn |
|
Vice President, Chief Financial Officer & Secretary |
Exhibit 32.1
CERTIFICATION Pursuant to 18 U.S.C. §
1350
The undersigned officer of ALLIED HEALTHCARE
PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on
Form 10-Q for the Company’s fiscal quarter ended September 30, 2014 (the "Report") fully complies with the requirements
of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.
|
/s/ Earl R. Refsland |
|
Earl R. Refsland |
|
President & Chief Executive Officer |
November 12, 2014
Exhibit 32.2
CERTIFICATION Pursuant to 18 U.S.C. §
1350
The undersigned officer of ALLIED HEALTHCARE
PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on
Form 10-Q for the Company’s fiscal quarter ended September 30, 2014 (the "Report") fully complies with the requirements
of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.
|
/s/ Daniel C. Dunn |
|
Daniel C. Dunn |
|
Vice President, Chief Financial Officer & Secretary |
November 12, 2014
Allied Healthcare Products (NASDAQ:AHPI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Allied Healthcare Products (NASDAQ:AHPI)
Historical Stock Chart
From Oct 2023 to Oct 2024